logo
France has banned smoking in parks, beaches and bus stops — but not restaurant patios

France has banned smoking in parks, beaches and bus stops — but not restaurant patios

CBC16 hours ago
Depending on who you ask, France's decision to exclude restaurant patios and terraces from its outdoor smoking ban is either a gross oversight, or a necessary preservation of French culture and liberty.
On Saturday, the country enacted a new ban on outdoor smoking at parks, sports venues, beaches, bus stops and outside schools, with fines of between 90 and 135 euros ($144 to $216 Cdn).
The government aims to curb cigarette use anywhere children gather in public, in line with President Emmanuel Macron's goal of ushering in the country's first "tobacco-free generation" by 2032.
Anti-smoking advocates welcomed the new rules, but derided the exclusion of restaurant and cafe patios and terraces, places they say are popular with families.
"These places regularly expose children to second-hand smoke and contribute precisely to the normalization of tobacco consumption in public spaces," the National Committee Against Smoking said in a statement.
But those who work in the food and drinks industry have vowed to do everything they can to keep the ban from reaching their outdoor tables.
"We really want to protect these last spaces of liberty, of freedom, where people — I mean smokers and non-smokers — are able to enjoy together a friendly and free atmosphere with a lot of pleasure," Franck Trouet, executive director of hospitality association Hotels and Restaurants of France, told As It Happens host Nil Köksal.
"It is one of the last spaces in France where you can have a cohabitation between smokers and non-smokers, and people are asking for that."
The goal is 'denormalization'
Philippe Bergerot, president of the French League Against Cancer, says the new restrictions are designed to promote the "denormalization" of smoking.
That's a huge challenge in a country where smoking is baked into the culture, romanticized in the media and seen to many as a symbol of liberty.
"In people's minds, smoking is normal," Bergerot said. "In France, we still have this mindset of saying, 'This is a law that restricts freedom.'"
But Health Minister Catherine Vautrin says the freedom to smoke "ends where children's right to breathe fresh air begins."
While second-hand smoke in enclosed spaces poses a greater risk, a number of studies have linked second-hand smoke in outdoor spaces to increased nicotine exposure and other negative health effects.
"Where there are children, tobacco must disappear," Vautrin told Ouest-France ahead of the ban.
Smoking has been declining in France steadily over the last decade, according to government data.
It's been illegal to smoke inside restaurants, bars and public buildings since a series of bans in 2007 and 2008, and taxes on cigarettes have risen sharply over the years.
But more than 30 per cent of French adults still smoke cigarettes, most of them daily. That's one of the higher rates in Europe and globally.
The Health Ministry says more than 200 people in France die each day of tobacco-related illness, adding up to 75,000 deaths a year.
The ministry says it's particularly concerned that tobacco remains popular among young people, citing public health statistics showing that 15 per cent of 17-year-olds smoke.
Parisians divided
French residents, meanwhile, remain divided.
Parisian Natacha Uzan said she welcomed the end of smoking in restaurants, but she believes the new rules have gone too far.
"Now outside, in parks, I find it becoming a bit repressive," she said.
Parisian Anabelle Cermell, on the other hand, welcomed the rules, which she says will protect her three-year-old son.
"I tell myself, oh, it's really not ideal for him, but there's not much I can do about it, or I would have to ... not take the bus, not go to parks," she said.
Trouet worries that banning cigarettes in parks and beaches is just the first step, and that terraces and patios will be targeted next.
If that happens, he says customers who smoke will be forced onto the streets, causing a nuisance for passersby and littering the city.
Still, he acknowledged that some non-smoking customers are irritated by the second-hand smoke on patios and terraces.
"I see that sometimes, and I always answer the same thing: It belongs to the owner of the cafe or the restaurant to decide if he wants to ban smoking on his terrace. He has the right," Trouet said. "It is a question of freedom, of liberty, as we say in France."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Australian man dies from ‘extremely rare' bat bite virus
Australian man dies from ‘extremely rare' bat bite virus

CTV News

time28 minutes ago

  • CTV News

Australian man dies from ‘extremely rare' bat bite virus

Sydney, Australia -- An Australian man has died from an 'extremely rare' rabies-like infection transmitted by a bat bite, health officials said Thursday. The man in his 50s was bitten by a bat carrying Australian bat lyssavirus several months ago, the health service in New South Wales said. 'We express our sincere condolences to the man's family and friends for their tragic loss,' NSW Health said in a statement. 'While it is extremely rare to see a case of Australian bat lyssavirus, there is no effective treatment for it.' The man from northern New South Wales, who has not been identified, was this week listed as being in a 'critical condition' in hospital. Officials said he was treated following the bite and they were investigating to see whether other exposures or factors played a role in his illness. The virus -- a close relative to rabies, which does not exist in Australia -- is transmitted when bat saliva enters the human body through a bite or scratch. First symptoms can take days or years to appear. Early signs of the disease are flu-like -- a headache, fever and fatigue, the health service said. The victim's condition rapidly deteriorates, leading to paralysis, delirium, convulsions and death. There were only three previous cases of human infection by Australian bat lyssavirus since it was first identified in 1996 -- all of them fatal. 'Coma and death' People should avoid touching or handling bats, as any bat in Australia could carry lyssavirus, the New South Wales health service said. Only wildlife handlers who are trained, protected, and vaccinated should interact with the flying mammals, it warned. 'If you or someone you know is bitten or scratched by a bat, you need to wash the wound thoroughly for 15 minutes right away with soap and water and apply an antiseptic with anti-virus action,' it said. 'Patients then require treatment with rabies immunoglobulin and rabies vaccine.' The virus has been found in species of flying foxes and insect-eating microbats, NSW Health said. The species of bat involved in the latest fatality has not been identified. 'Australian bat lyssavirus is very closely related to rabies and will cause death in susceptible people if they become infected and are not treated quickly,' said James Gilkerson, infectious diseases expert at the University of Melbourne. The virus was first identified in May 1996 by scientists at the national science agency CSIRO, who examined brain tissue from a flying fox that had been showing 'nervous signs' in New South Wales. Later that year, a bat handler in Queensland became ill. 'The initial numbness and weakness suffered in her arm progressed to coma and death,' the science agency said in an online document on the virus. 'Two further cases in Queensland -- a woman in 1998 and an eight year old boy in 2013 -- resulted in death after being bitten or scratched by a bat,' it said. There are subtle differences between the lyssavirus in flying foxes and insectivorous bats, the science agency has found. Infected bats can transmit the virus to people, other bats and other mammals.

WHO pushes countries to raise prices on sugary drinks, alcohol and tobacco by 50%
WHO pushes countries to raise prices on sugary drinks, alcohol and tobacco by 50%

CTV News

time3 hours ago

  • CTV News

WHO pushes countries to raise prices on sugary drinks, alcohol and tobacco by 50%

LONDON -- The World Health Organization is pushing countries to raise the prices of sugary drinks, alcohol and tobacco by 50% over the next 10 years through taxation, its strongest backing yet for taxes to help tackle chronic public health problems. The United Nations health agency said the move would help cut consumption of the products, which contribute to diseases like diabetes and some cancers, as well as raising money at a time when development aid is shrinking and public debt rising. 'Health taxes are one of the most efficient tools we have,' said Jeremy Farrar, WHO assistant-director general of health promotion and disease prevention and control. 'It's time to act.' The WHO launched the push, which it called '3 by 35' at the UN Finance for Development conference in Seville. WHO said that its tax initiative could raise US$1 trillion by 2035 based on evidence from health taxes in countries such as Colombia and South Africa. The WHO has backed tobacco taxes and price rises for decades, and has called for taxes on alcohol and sugary drinks in recent years, but this is the first time it has suggested a target price rise for all three products. WHO Director-General Dr Tedros Adhanom Ghebreyesus told the conference that the taxes could help governments 'adjust to the new reality' and bolster their own health systems with the money raised. Many low and middle-income countries are coping with cuts to aid spending led by the United States, which is not attending the Seville conference. The U.S. is also in the process of withdrawing from the WHO. From $4 to $10 As an example, the initiative would mean a government in a middle-income country raising taxes on the product to push the price up from $4 today to $10 by 2035, taking into account inflation, said WHO health economist Guillermo Sandoval. Nearly 140 countries had already raised tobacco taxes and therefore prices by over 50% on average between 2012 and 2022, the WHO added. Sandoval said the WHO was also considering broader taxation recommendations, including on ultra-processed food, after the agency finalizes its definition of that type of food in the coming months. But he added that the agency expected pushback from the industries involved. 'It's deeply concerning that the World Health Organization (WHO) continues to disregard over a decade of clear evidence showing that taxing sugar-sweetened beverages has never improved health outcomes or reduced obesity in any country,' said Kate Loatman, executive director of the International Council of Beverages Associations, adding that the industry was working on options to support health. 'The World Health Organization's suggestion that raising taxes will prevent alcohol-related harm is misguided,' said Amanda Berger, senior vice-president of science and research at the Distilled Spirits Council, adding that it would not prevent alcohol abuse. The tax initiative is backed by Bloomberg Philanthropies, the World Bank and the Organization for Economic Co-operation and Development (OECD), and involves support for countries who want to take action. Reporting by Jennifer Rigby and Virginia Furness; Editing by David Evans and Kate Mayberry, Reuters

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta

National Post

time13 hours ago

  • National Post

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta

Article content Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle ® (follitropin delta); alongside its existing unique algorithm-based dosing Article content PARIS — Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications. 1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrieved. Article content Currently, follitropin delta is approved for use via a dosing algorithm based on serum anti-Müllerian Hormone (AMH) and bodyweight individualised for each patient, and aims to obtain an ovarian response which is associated with a favourable safety/efficacy profile. The clinical value of this approach has been well established 4,5,6,7,8, particularly in treatment-naïve patients where the algorithm aims to achieve 8–14 retrieved oocytes while minimising the risk of ovarian hyperstimulation syndrome (OHSS) to optimise the live birth rate in a fresh and frozen transfer cycle. 4,5,6,7,8 Key Findings: Ovarian Response: Both treatment groups achieved a mean of 9.9 oocytes retrieved, indicating similar efficacy Clinical Pregnancy Rates: Clinical pregnancy rates were similar for follitropin delta 31.6% versus 31.0% for follitropin alfa Drug Product Usage: After measurement unit conversion, the mean total dose patients were exposed to was numerically lower for follitropin delta (143.7±33.6 µg) than follitropin alfa (154.3±23.1 µg or 2,105±315 IU) OHSS Rates: Early OHSS rates were low (2.5% for follitropin delta and 3.0% for follitropin alfa), with no cycle cancellations due to excessive ovarian response on either arm of the study. Dr Andrea Bernabeu, Medical Director at Instituto Bernabeu and principal investigator of the ADAPT-1 trial, said: 'No patients we see as fertility doctors are the same and the ability to optimise therapy based on patients age, treatment goal and whether they have a high or low response to follicular stimulation are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta.' Article content Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: 'The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities.' Article content About GnRH protocols Article content Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI. 7,8 About Follitropin Delta (Rekovelle ®) Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response. 3 It is the first rFSH derived from a human cell line (PER.C6 ® cell line). Follitropin delta is structurally and biochemically distinct from other existing rFSH gonadotrophins. 3,4 Follitropin delta is approved in certain markets for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as IVF or ICSI cycle. The individualised dosing of follitropin delta is determined using an approved algorithm, based on a woman's AMH level and body weight. 3,5 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response. 5,6 The follitropin delta dose should be based on AMH level, measured using the ELECSYS AMH Plus immunoassay from Roche, the ACCESS AMH Advanced from Beckman Coulter, or LUMIPULSE G AMH from Fujirebio. 3 About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in areas of gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Article content REFERENCES Article content 1 – Arce JC, Larsson P, Garcia-Velasco JA; Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa; RBMO; 2020 Article content 2 – Yang R, Zhang Y, Liang X et al; Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization / intracytoplasmic sperm injection; Reproductive Biology and Endocrinology; 2022 Article content 3 – Clinical page: (Accessed June 2025) Article content 4 – Andersen, A. N., Nelson, S. M., Fauser, B. et al. (2017). Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility, 107(2), 387-396. Article content 5 – Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. PMID: 30594482. Article content 6 – Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-18. PubMed PMID: 33722477. Epub 2021/03/17. Article content 7 – Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021 Jun 28;36(9):2452-62. PubMed PMID: 34179971. Epub 2021/06/29. Article content 8 – Blockeel C, Griesinger G, Rago R, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology. 2022 Dec 22;13:992677. PMID: 36619578. Article content Article content Article content Article content Article content Contacts Article content For more information, please contact Article content M Article content atthew Worrall Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store